Medpace: A Science-Focused Clinical Trial Leader
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Medpace, a science-focused clinical trials company, has seen its stock drop by 11.2% over the past six months, while the S&P 500 fell by 5.5%. Despite this, the companys core business is thriving, with organic revenue growing at an average of 15.9% year over year for the last two years. Earnings per share have also grown at a 31.7% compound annual rate over five years, outpacing revenue growth and proving profitable scaling. Free cash flow margin has increased by 6.4 percentage points in the last five years, reaching 26.9% in the trailing twelve months. With a forward earnings multiple of 26.4, Medpace appears to be a strong contender with solid momentum.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/d153ec45e669bd2f